Cellectis

Cellectis Days Payable Outstanding

The Days Payable Outstanding (DPO) of Cellectis (ALCLS.PA) as of Oct 21, 2026 is 302.02. In the previous year, Days Payable Outstanding (DPO) was 741.93 — a change of -59.29% (lower).

Days Payable Outstanding

302.02

YoY

-59.29%

Last updated:

Days Payable Outstanding (DPO) of Cellectis is 2025 302.02 . Days Payable Outstanding (DPO) of Cellectis was 2024 741.93 . It decreases by -59.29% lower compared to the previous year.

The Cellectis Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
2,116.57 USD
Jan 1, 2019
937.62 USD
Jan 1, 2020
247.62 USD
Jan 1, 2021
239.09 USD
Jan 1, 2022
4,419.55 USD
Jan 1, 2023
9,443.94 USD
Jan 1, 2024
741.93 USD
Jan 1, 2025
302.02 USD
The Cellectis Days Payable Outstanding history
YEARDays Payable OutstandingYoY
302.02-59.29%
741.93-92.14%
9,443.94+113.69%
4,419.55+1,748.46%
239.09-3.44%
247.62-73.59%
937.62-55.70%
2,116.57+60.60%
1,317.90-37.17%
2,097.44+115.13%
974.96-17.29%
1,178.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Days Payable Outstanding (DPO) of Cellectis is 302.02 in 2025.

Days Payable Outstanding (DPO) of Cellectis changed from 741.93 to 302.02, representing a -59.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Cellectis since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cellectis

All Key Metrics — Cellectis